{
  "_id": "3c19f1b832640797d2294d8623660d374a9a575c90026fdc4a7bc0158995b4e5",
  "feed": "wall-street-journal",
  "title": "What Biotech ETFs Might Be Right for Your Portfolio? A look at the offerings in what has become a hot sector this summer",
  "text": "<p>Here are some of the most prominent biotechnology ETFs and some key facts:</p><p>iShares Biotechnology ETF (IBB): Mostly large-cap companies</p><p>* The market-cap-weighted index is up 8.5% this quarter through Friday.</p><p>* Top holdings as of Aug. 12 include Vertex Pharmaceuticals Inc., Gilead Sciences Inc., Amgen Inc. and Regeneron Pharmaceuticals Inc.</p><p>* Market value: $8.39 billion</p><p>* Expense ratio: 0.44%</p><p>SPDR S&amp;P Biotech ETF (XBI): Mostly small and midcap companies</p><p>* The equal-weighted index is up 17.5% this quarter.</p><p>* Top holdings as of Aug. 18 include Global Blood Therapeutics Inc., Karuna Therapeutics Inc. and ChemoCentryx Inc.</p><p>* Market value: $8.25 billion</p><p>* Expense ratio: 0.35%</p><p>ARK Genomic Revolution ETF (ARKG): Mostly small and midcap companies</p><p>* The (methodology undisclosed) index is up 15.7% this quarter.</p><p>* Top holdings as of Aug. 18 include Exact Sciences Corp., Signify Health Inc. Class A, Ionis Pharmaceuticals Inc.</p><p>* Market value: $2.92 billion</p><p>* Expense ratio: 0.75%</p><p>First Trust NYSE Arca Biotechnology Index Fund (FBT): Mostly large and midcap companies</p><p>* The equal-weighted index is up 5.7% this quarter.</p><p>* Top holdings as of Aug. 18 include Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Agios Pharmaceuticals Inc. and FibroGen Inc.</p><p>* Market value: $1.4 billion</p><p>* Expense ratio: 0.55%</p><p>You will notice there are different ways of making up an ETF. Market-cap-weighted ETFs, which hold more of a given constituent company the larger that firm is by market value, generally offer greater exposure to large companies, while equal-weighted ETFs often focus on smaller firms. Most biotech companies are unprofitable as they pursue drug development and commercialization.</p><p>\"If you're going to play biotech, play biotech more from the market-cap-weighted versus the equal-weighted,\" says Jon Maier, chief investment officer at Global X ETFs.</p><p>SHARE YOUR THOUGHTS</p><p>Which biotech ETFs are you most interested in right now? Join the conversation below.</p><p>His fund manages the Global X Genomics &amp; Biotechnology ETF, which is up 17.8% this quarter. This market-cap-weighted ETF primarily has midcap and small companies with its top holdings as of Aug. 18, including Sarepta Therapeutics, Beam Therapeutics Inc. and Alnylam Pharmaceuticals.</p><p>Biotechs are also a sizable part of the Russell 2000 index of small-cap companies, though the index provider recently cut dozens of biotechs from that index as part of a regular culling of laggards.</p><p>The Russell 2000 now includes 189 biotech stocks, according to Bank of America U.S. equity strategist Jill Carey Hall. The broader small-cap index is up 10.2% in the past three months, while its biotech index is up 34.4% in the same period.</p><p>\"The field has gotten more competitive, but the pace of innovation has continued to accelerate, and this is a sector that can have huge implications,\" said Dr. Brian Abrahams, managing director and head of biotechnology equity research at RBC Capital Markets.</p><p>Write to Pia Singh at Pia.Singh@wsj.com</p><p>What Biotech ETFs Might Be Right for Your Portfolio?</p>",
  "published": "2022-08-19T21:04:00.000Z",
  "tags": [
    {
      "id": "US0311621009",
      "nexusId": "10036019",
      "name": "Amgen Inc.",
      "confidence": 0.7,
      "offsets": [
        {
          "start": 295,
          "end": 305
        }
      ],
      "weightsV2": {
        "weight": 0.69820994,
        "baseWeight": 1.0,
        "expansionWeight": 0.0,
        "ontologyWeight": -0.40126306,
        "tagPositionWeight": 0.099473,
        "titleWeight": 0.0
      },
      "typeRank": 5
    }
  ]
}